Skip to main content
. 2011 Nov 14;4:46. doi: 10.1186/1756-8722-4-46

Table 5.

CR rates of CAG and non-CAG regimens in AML patients

Study Year Total No.
patients 		No. Patients No. CR CR %
CAG Non-CAG CAG Non-CAG CAG Non-CAG
Saito [35] 1995 35 18 171 15 11 83 65
Chen [46] 2008 75 34 412 23 16 68 39
Sang [47] 2008 45 23 223 9 7 39 32
Bian [48] 2008 46 26 264 20 10 77 38
Zhu [50] 2009 50 30 205 14 6 47 30
Li [53] 2010 38 18 206 14 14 78 70
Feng [52] 2010 32 16 167 9 7 56 44

Abbreviation: AML: acute myeloid leukemia; CR: complete remission; CAG: cytarabine, aclarubicin and G-CSF;

1: HD-Ara-C+M/ME (high-dose cytarabine plus mitoxantrone with or without etoposide);

2: TA/HA (pirarubicin plus cytarabine/homoharringtonine plus cytarabine);

3: DA/HA/IA (daunorubicin plus cytarabine/homoharringtonine plus cytarabine/idarubicin plus cytarabine);

4: DAH/MAE (daunorubicin plus cytarabine plus homoharringtonine/mitoxantrone plus cytarabine plus etoposide);

5: DA/IA/MA (daunorubicin plus cytarabine/idarubicin plus cytarabine/mitoxantrone plus cytarabine);

6: HAG (homoharringtonine plus cytarabine plus GCSF);

7: HA (homoharringtonine plus cytarabine).